



**Prof. Bruce A Littlefield
Distinguished Scientist and
Head, Translational Medicine
Global Oncology Medical
Affairs, Eisai Inc.**

Andover, Massachusetts, USA

**'Beyond Antimitotic Effects
To Complex Changes In
Tumour Biology'**

Dr. Littlefield holds the dual positions of Distinguished Scientist and Head, Translational Medicine in the Global Oncology Medical Affairs group at Eisai, a global pharmaceutical company headquartered in Tokyo. A biochemist by training, Dr. Littlefield first joined Eisai in 1990 and since that time has overseen numerous natural product-based oncology drug discovery programs. One such program, initiated at Eisai by Dr. Littlefield in 1992 together with Professor Yoshito Kishi of Harvard, was based on the marine sponge natural product halichondrin B. This program led to development of eribulin (Halaven®), currently approved in 60 countries worldwide for treatment of certain patients with advanced breast cancer, with recent additional approvals for advanced liposarcoma in the USA, EU and Japan. Dr. Littlefield has published widely in the cancer research area, holds numerous drug development-related patents, and is a frequent lecturer at universities, medical centers and scientific conferences in the US and abroad. In addition to working at Eisai, Dr. Littlefield has held faculty positions at both Yale and Harvard Medical Schools, most recently 2009-2011, when he temporarily joined Harvard to oversee scientific development of a new natural products research program, before returning to Eisai in his current capacity in 2011.



Thursday, 26/10/2017, 2-3pm

Proudly Sponsored by



Lowy Seminar Room level 4

